Clinical trials · Baltimore, MD
Cancer clinical trials in Baltimore
We’re tracking 816 recruiting cancer studies with a site in or near Baltimore — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Baltimore
- NCT05281471RecruitingPhase 3
Tested drug for platinum-resistant ovarian cancer with bevacizumab
This Phase 3 trial tests a treatment made of an investigational gene-based drug plus standard “platinum” chemotherapy and bevacizumab, compared with standard chemotherapy and bevacizumab. It’s for ovarian/fallopian tube/primary peritoneal cancers that have not responded to platinum chemotherapy or came back quickly.
Silver Spring, MarylandAges 18 years+ - NCT04196257RecruitingPhase 1
Early-dose trial of BP1001-A for advanced or recurrent solid tumors
This Phase 1 trial studies BP1001-A in people with advanced or recurring solid cancers to find a safe dose and learn how the treatment works. You may be asked for tumor biopsies before and possibly after treatment to see how the cancer responds.
Silver Spring, MarylandAges 18 years+ - NCT06731478RecruitingPhase 3
New drug combo for first treatment of HER2-positive stomach cancer
This trial tests a new targeted drug (TDXd) combined with chemotherapy, pembrolizumab, and trastuzumab for people with HER2-positive stomach or gastroesophageal junction cancer that has spread or cannot be removed by surgery. It aims to see if this combination works better than standard treatments as a first therapy.
Silver Spring, MarylandAges 18 years+ - NCT05797831RecruitingPhase 2/Phase 3
Maintenance treatment for TP53-wildtype endometrial cancer
This trial tests navtemadlin as a maintenance (ongoing) treatment to help prevent endometrial cancer from coming back after chemotherapy works. It is mainly for people whose cancer has certain genetic features (TP53 “wildtype”) and who had a strong response to first-line taxane–platinum chemo.
Silver Spring, MarylandAges 18 years+ - NCT06393374RecruitingPhase 3
Study of a new drug combination for residual TNBC after initial treatment
This trial tests a new combination of two drugs (sacituzumab tirumotecan and pembrolizumab) compared to standard chemotherapy for people with triple-negative breast cancer that did not fully respond to initial treatment. It aims to see if this combination helps prevent cancer from coming back.
Silver Spring, MarylandAges 18 years+ - NCT03723928Recruiting
Blood test–guided monitoring for metastatic breast cancer treatment
This study checks whether specific blood “tumor marker” levels can help monitor how hormone receptor–positive, HER2-negative metastatic breast cancer responds to first-line therapy. It uses regular blood tests (and sometimes scans) to see if this marker-based monitoring is useful and reliable.
Silver Spring, MarylandAges 18 years+ - NCT06764875RecruitingPhase 3
New drug combo for HER2-positive stomach cancer
This trial tests a new immunotherapy called rilvegostomig combined with standard chemotherapy and a targeted therapy (trastuzumab deruxtecan) for people with advanced HER2-positive stomach or gastroesophageal junction cancer that has not been treated before.
Silver Spring, MarylandAges 18 years+ - NCT07218146RecruitingPhase 3
Study of ZL-1310 vs Standard Care for Relapsed Small Cell Lung Cancer
This trial tests a new drug, ZL-1310, against standard treatments for people with small cell lung cancer that has returned after initial therapy. The goal is to see if ZL-1310 works better than other options.
Silver Spring, MarylandAges 18 years+ - NCT05128825RecruitingPhase 2
Test drug azenosertib for platinum-resistant ovarian cancer
This Phase 2 trial tests azenosertib to treat platinum-resistant high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. It looks for whether the drug can shrink tumors and improve outcomes in people whose cancer has returned after platinum chemotherapy.
Rockville, MarylandAges 18 years+ - NCT04888936Recruiting
Study families with genetic RAS syndromes, including adults and children
This study looks at people with certain inherited genetic conditions called RASopathies and their family members. It helps researchers understand these conditions and how genetic changes run in families, which may improve future care.
Rockville, MarylandAges 1 month–99 years - NCT05579366RecruitingPhase 1/Phase 2
Study drug for advanced ovarian and other solid cancers
This Phase 1/2 trial studies Rinatabart Sesutecan to treat advanced cancers, with special focus on certain ovarian cancer types. It’s meant for people whose cancer has come back or has not responded to prior treatments.
Rockville, MarylandAges 18 years+ - NCT07365995RecruitingPhase 3
New drug for advanced prostate cancer vs. standard chemo
This trial tests a new drug called BNT324 against the standard chemotherapy docetaxel for men with advanced prostate cancer that has stopped responding to hormone therapy. It aims to see if the new treatment can help control the cancer better.
Rockville, MarylandAges 18 years+ - NCT05350761Recruiting
Study rare tumors and inherited cancer risk in families
This study looks at people who have rare or unusual cancers or who may have an inherited (family) risk for cancer. It helps researchers learn what genetic or other factors might be involved by collecting family history and medical records, including pathology slides.
Rockville, MarylandAges Any age - NCT05584826RecruitingPhase 2
MDMA therapy for cancer patients and their partner’s distress
This Phase 2 study tests whether MDMA-assisted therapy can reduce adjustment-related distress in cancer patients who are paired with a loved one who is also concerned. It may help the patient and their significant other cope better through structured therapy sessions, with safety checks before and after each session.
Rockville, MarylandAges 18 years+ - NCT03460977RecruitingPhase 1
Mevrometostat trial for hormone-resistant prostate cancer
This Phase 1 study tests mevrometostat (PF 06821497) in people with castration-resistant prostate cancer to see if it’s safe and how the body responds to it. It may be an option if your cancer is no longer controlled by hormone therapy and your organ health tests are within limits.
Rockville, MarylandAges 18 years+ - NCT01247597Recruiting
Study of DICER1-related tumor history in families
This study follows people affected by DICER1-related tumors (and sometimes family members) to better understand how these conditions develop over time. It may help families by improving knowledge and guiding genetic counseling and future care.
Rockville, MarylandAges 1 month–99 years - NCT06623422RecruitingPhase 3
Vaccine plus Keytruda for lung cancer after surgery
This trial tests combining a cancer vaccine (V940) with the immunotherapy drug pembrolizumab (Keytruda) for people with non-small cell lung cancer that was treated with chemo and Keytruda before surgery but wasn't completely removed. The goal is to see if adding the vaccine helps prevent the cancer from coming back.
Rockville, MarylandAges 18 years+ - NCT00027274Recruiting
Cancer risk in inherited bone marrow failure syndromes
This study looks at why people with inherited bone marrow failure syndromes (rare genetic conditions affecting blood cell production) have higher cancer risk. Researchers want to understand the genetic and medical factors that increase cancer likelihood, which could help doctors monitor and protect affected patients and their families.
Rockville, MarylandAges 1 day–100 years - NCT04486833RecruitingPhase 1/Phase 2
Genetic-targeted drug plus gene medicine for EGFR lung cancer
This trial studies a gene-based treatment added to osimertinib (a targeted lung cancer pill) for advanced EGFR-mutant lung cancer that has started growing again on osimertinib. It may help by attacking the cancer with both its usual target treatment and an added genetic approach.
Rockville, MarylandAges 18 years+ - NCT04322383RecruitingPhase 2
Binimetinib for relapsed or refractory hairy cell leukemia
This trial tests a drug called binimetinib in people with a type of leukemia that has come back or not responded to treatment. It is for those whose cancer cells do not have a BRAF mutation.
Bethesda, MarylandAges 18 years+ - NCT04086485RecruitingPhase 1/Phase 2
Lu-177 dotatate plus olaparib for inoperable neuroendocrine tumors
This study tests whether combining Lu-177 dotatate (a targeted radiation treatment) with olaparib (a targeted pill) can shrink or slow growth of inoperable gastroenteropancreatic neuroendocrine tumors. It’s designed for tumors that show the right “targets” on a special scan and that have started to progress despite standard care.
Bethesda, MarylandAges 18–100 - NCT06222203Recruiting
Monitoring for tumor changes in people with NF1
This study tracks people with NF1 to watch for when benign nerve tumors turn cancerous. It uses regular MRI scans to catch changes early, which could help guide treatment decisions.
Bethesda, MarylandAges 3–120 - NCT06804785Recruiting
AI-assisted MRI reading for prostate cancer diagnosis
This trial is testing a new 'smart' system that combines artificial intelligence (AI) with doctor oversight to better read prostate MRI scans and guide decisions for men who have not yet had a biopsy. It may help avoid unnecessary biopsies while catching cancer early.
Bethesda, MarylandAges 18–89 - NCT06223542RecruitingPhase 1
TAK-243 for advanced cancers that haven't responded to other treatments
This trial tests a new drug called TAK-243 for people with advanced cancers (solid tumors or lymphomas) that have not responded to other treatments. It aims to see if the drug is safe and how well it works.
Bethesda, MarylandAges 18 years+
Hear when a new Cancer trial opens near Baltimore, MD
We’ll email you when one opens near Baltimore, MD — at most once a week, no account needed, unsubscribe anytime.
Cancer trials in other cities
Where these studies are running near Baltimore
Institutions with a site for the recruiting cancer studies listed above.
- Maryland Oncology Hematology, P.A. · 8 studies
- National Institutes of Health Clinical Center · 8 studies
- Holy Cross Hospital · 4 studies
- National Cancer Institute - Shady Grove · 4 studies
- National Cancer Institute (NCI)
- Research Site
- Sunstone Therapies
- Zai Lab Site 02003
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting cancer studies in Maryland.
Common questions
- Are there cancer clinical trials near Baltimore?
- Yes. We're currently tracking 816 recruiting cancer studies with a site near Baltimore, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study near Baltimore?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Baltimore to take part?
- Not necessarily. These studies have a site near Baltimore, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open near Baltimore regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.